FDA explains plans to bolster cell and gene therapy approvals through wider messaging

Wilson Bryan director of the US Food and Drug Administration’s Office of Tissues and Advanced Therapies (OTA) in the agency’s Center for Biologics Evaluation and Research, told a 19 May meeting of the Association for Cell and Gene Therapies (ASGCT) that the division is undertaking a series of internal measures to improve communications with sponsors and to widen its messaging.